Search Results

The DUALTO™ electrosurgical generator is designed to offer a simplified user experience, access to Polyphonic™ Fleet digital device management, and flexible application of monopolar, bipolar, ultrasonic, and advanced bipolar energy devices for open and minimally invasive surgery DUALTO will be showcased at the Association of periOperative Registered Nurses Global Surgical Conference & Expo on April 5-8, 2025 The DUALTO Energy System recently received 510(k) clearance by the U.S. Food & Drug Administration1

J&J CareCommunity is empowering frontline health workers by equipping nurses and community health workers with the skills, resources and opportunities needed to strengthen global healthcare and expand access to quality care.

Penny Heaton, M.D., is the Global Head of the Johnson & Johnson Office of the Chief Medical Officer which, aligned with Our Credo, keeps patients at the center of the company’s efforts to tackle the world’s toughest health challenges through its leadership in Medical Safety, Epidemiology, Bioethics and product Lifecycle Management.

•New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases •Delivering on Company’s plans for increased U.S. investment, $2 billion+ advanced biologics facility will add more than 5,000 high-wage manufacturing and construction jobs in North Carolina. •Investment will create an estimated economic impact of $3 billion statewide during first 10 years of site operation

Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs Includes four planned new manufacturing facilities, with ground-breaking today in North Carolina on $2 billion+ facility Total Company U.S. economic impact estimated to be more than $100 billion per year

TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA® is the only IL-23i to show superiority versus STELARA® in all pooled endoscopic endpoints within a double-blinded registrational trial TREMFYA® approval in Crohn’s disease builds upon recent ulcerative colitis FDA approval, marking the fourth indication for this dual-acting IL-23i in the U.S.

Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regimen meets primary endpoint and enhances patient experience

Sjögren’s disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks the fourth nipocalimab FDA Fast Track designation

As the Founding Sponsor, J&J contributes $1 million to accelerate the creation of industry-aligned curricula and state-of-the-art training facilities at three leading New Jersey community colleges

Next-generation NVIDIA-powered AI navigation software elevates MONARCHTM Platform for Robotically Assisted Bronchoscopy